In:
The Journal of Immunology, The American Association of Immunologists, Vol. 198, No. 1_Supplement ( 2017-05-01), p. 213.9-213.9
Abstract:
Early detection of protein biomarkers is critical to the study of human disease (e.g. cancer, inflammation/autoimmunity, neurodegeneration). Basic research scientists as well as translational investigators require powerful protein quantitation tools that provide sensitive low-level detection of disease relevant protein analytes. ELISAs first developed in the 1970s and slightly improved upon over the years are still considered the gold standard, yet large sample consumption, limited sensitivity, and laborious workflows, leave room for improvement and innovation. Thermo Fisher Scientific, the worldwide leader in life science tools for researchers, is unveiling an affordable new platform for the next generation of high-sensitivity, ready-to-use immunoassays. Featuring serum compatible, TaqMan™ based Proximity Ligation Assay (PLA) and SiteClick™ antibody labeling technologies, this new assay combines the analyte specificity of high affinity antibody-antigen binding with the signal detection and amplification of real-time PCR. Key benefits of this platform include: - Greater sensitivity and dynamic range than traditional methods- Smaller sample consumption than traditional methods: 1–2 uL per sample- A fast, simplified workflow - 2 hr. sample-to-answer with no wash steps- The inclusion of an intuitive, robust multi-OS data analysis software- Workflow compatibility with any real-time PCR instrument Here, we highlight the immunoassay performance including sensitivity, dynamic range, spike-recovery, parallelism, linearity of dilution, and benchmarking to ELISA, all analyzed using a new software available through the Thermo Fisher Cloud.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.198.Supp.213.9
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2017
detail.hit.zdb_id:
1475085-5
Permalink